

Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Growth 2026-2032

<https://marketpublishers.com/r/GAA52C073858EN.html>

Date: July 2026

Pages: 116

Price: US\$ 3,660.00 (Single User License)

ID: GAA52C073858EN

Abstracts

The global Inactivated Mycoplasma Hyopneumoniae Vaccine market size is predicted to grow from US\$ 670 million in 2025 to US\$ 935 million in 2032; it is expected to grow at a CAGR of 4.9% from 2026 to 2032.

Inactivated Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product based on inactivated Mycoplasma hyopneumoniae antigen. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of enzootic pneumonia-related coughing, lung lesions, secondary infections and production performance losses. The product is usually supplied as an injectable emulsion or suspension, covering both monovalent inactivated vaccines and combination inactivated vaccines containing antigens such as porcine circovirus type 2. Key upstream materials include production strains, dedicated culture media, inactivating agents, adjuvants, buffers, stabilizers, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. On an ex-factory basis, global effective capacity of this product category is estimated at around 1.34 billion doses in 2025, with sales volume of approximately 1.083 billion doses and an average ex-factory price of about USD 0.63 per dose. The industry gross margin in 2025 is estimated at roughly 45%-65%, with multinational brands and multivalent vaccines usually at the upper end of the range, and local monovalent or regional products more commonly positioned in the middle to lower part of the range.

The market for inactivated Mycoplasma Hyopneumoniae Vaccine has established a mature application base, with demand mainly supported by the long-term need for

integrated respiratory disease control in commercial swine farms. As pig farming continues to move toward larger-scale, more intensive and more standardized management, farms are placing greater emphasis on stable vaccination programs, vaccine safety and herd-level protection. The product is widely used in piglet and nursery-stage immunization and serves not only as a basic preventive vaccine but also as an important management tool to reduce respiratory problems during the growing-finishing stage. Current competition is no longer limited to monovalent vaccine pricing, but is increasingly shaped by product stability, duration of immunity, farm service capability and the value of integrated health solutions.

Looking ahead, combination vaccines and one-shot immunization programs are expected to gain further importance, especially products linked with the prevention needs of porcine circovirus, bacterial respiratory pathogens and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. At the same time, adjuvant systems, antigen purification, strain adaptability and batch-to-batch consistency will become key directions for product upgrading, driving the industry from traditional monovalent vaccine competition toward higher-quality combination vaccines and scenario-based immunization programs.

The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although *Mycoplasma hyopneumoniae* infection is usually not characterized by acute high mortality, its long-term impact on feed conversion, average daily gain, lung lesions and secondary infections can create hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, product consistency and whole-cycle herd health value, rather than purchase price alone.

Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of combination

vaccines may also limit market penetration. Meanwhile, new vaccine routes, differences in local strains, regulatory approval requirements and cold-chain distribution conditions add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.

LP Information, Inc. (LPI) ' newest research report, the "Inactivated Mycoplasma Hyopneumoniae Vaccine Industry Forecast" looks at past sales and reviews total world Inactivated Mycoplasma Hyopneumoniae Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Inactivated Mycoplasma Hyopneumoniae Vaccine sales for 2026 through 2032. With Inactivated Mycoplasma Hyopneumoniae Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Inactivated Mycoplasma Hyopneumoniae Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Inactivated Mycoplasma Hyopneumoniae Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Inactivated Mycoplasma Hyopneumoniae Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Inactivated Mycoplasma Hyopneumoniae Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Inactivated Mycoplasma Hyopneumoniae Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Inactivated Mycoplasma Hyopneumoniae Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Inactivated Mycoplasma Hyopneumoniae Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Single Vaccine

Dual Vaccine

Others

Segmentation by Adjuvant Type:

Oil-adjuvanted

Aqueous-adjuvanted

Others

Segmentation by Dose Pack Size:

Small Pack (Below 20 Doses per Vial)

Medium Pack (20-50 Doses per Vial)

Large Pack (Above 50 Doses per Vial)

Segmentation by Application:

Large-scale Pig Farming Groups

Breeding Pig Farms

Animal Health Service Providers

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Zoetis

Boehringer Ingelheim

Merck Animal Health

Ceva Santé Animale

HIPRA

Bioveta

Vaxxinova

Nisseiken

Kyoto Biken Laboratories

Pulike Biological Engineering

Wuhan Keqian Biology

Huapai Biotechnology

TianKang Pharmaceutical

Qilu Animal Health

Key Questions Addressed in this Report

What is the 10-year outlook for the global Inactivated Mycoplasma Hyopneumoniae Vaccine market?

What factors are driving Inactivated Mycoplasma Hyopneumoniae Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Inactivated Mycoplasma Hyopneumoniae Vaccine market opportunities vary by end market size?

How does Inactivated Mycoplasma Hyopneumoniae Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Inactivated Mycoplasma Hyopneumoniae Vaccine by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Inactivated Mycoplasma Hyopneumoniae Vaccine by Country/Region, 2021, 2025 & 2032

2.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Segment by Type

2.2.1 Single Vaccine

2.2.2 Dual Vaccine

2.2.3 Others

2.2.4 Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type

2.2.4.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

2.2.4.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Type (2021-2026)

2.2.4.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026)

2.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Segment by Adjuvant Type

2.3.1 Oil-adjuvanted

2.3.2 Aqueous-adjuvanted

2.3.3 Others

2.3.4 Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Adjuvant Type

2.3.4.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share

by Adjuvant Type (2021-2026)

2.3.4.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Adjuvant Type (2021-2026)

2.3.4.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Adjuvant Type (2021-2026)

2.4 Inactivated Mycoplasma Hyopneumoniae Vaccine Segment by Dose Pack Size

2.4.1 Small Pack (Below 20 Doses per Vial)

2.4.2 Medium Pack (20-50 Doses per Vial)

2.4.3 Large Pack (Above 50 Doses per Vial)

2.4.4 Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size

2.4.4.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)

2.4.4.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)

2.4.4.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026)

2.5 Inactivated Mycoplasma Hyopneumoniae Vaccine Segment by Application

2.5.1 Large-scale Pig Farming Groups

2.5.2 Breeding Pig Farms

2.5.3 Animal Health Service Providers

2.5.4 Others

2.5.5 Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application

2.5.5.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)

2.5.5.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Application (2021-2026)

2.5.5.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Breakdown Data by Company

3.1.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Sales by Company (2021-2026)

3.1.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)

3.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Company (2021-2026)

- 3.2.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026)
- 3.2.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)
- 3.3 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Company
- 3.4 Key Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Product Location Distribution
 - 3.4.2 Players Inactivated Mycoplasma Hyopneumoniae Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.6 New Products and Potential Entrants
- 3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR INACTIVATED MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION

- 4.1 World Historic Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Geographic Region (2021-2026)
 - 4.1.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Sales by Geographic Region (2021-2026)
 - 4.1.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Geographic Region (2021-2026)
- 4.2 World Historic Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size by Country/Region (2021-2026)
 - 4.2.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Sales by Country/Region (2021-2026)
 - 4.2.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Growth
- 4.4 APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Growth
- 4.5 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Growth
- 4.6 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Growth

5 AMERICAS

5.1 Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country

5.1.1 Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)

5.1.2 Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)

5.2 Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

5.3 Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Region

6.1.1 APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026)

6.1.2 APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026)

6.2 APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

6.3 APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine by Country

7.1.1 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)

7.1.2 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Country

(2021-2026)

7.2 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type

(2021-2026)

7.3 Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application

(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine by Country

8.1.1 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)

8.1.2 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)

8.2 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

8.3 Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine

10.3 Manufacturing Process Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine

10.4 Industry Chain Structure of Inactivated Mycoplasma Hyopneumoniae Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Inactivated Mycoplasma Hyopneumoniae Vaccine Distributors

11.3 Inactivated Mycoplasma Hyopneumoniae Vaccine Customer

12 WORLD FORECAST REVIEW FOR INACTIVATED MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION

12.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Size Forecast by Region

12.1.1 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Forecast by Region (2027-2032)

12.1.2 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Forecast by Type (2027-2032)

12.7 Global Inactivated Mycoplasma Hyopneumoniae Vaccine Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Zoetis

13.1.1 Zoetis Company Information

13.1.2 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

13.1.3 Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Zoetis Main Business Overview

- 13.1.5 Zoetis Latest Developments
- 13.2 Boehringer Ingelheim
 - 13.2.1 Boehringer Ingelheim Company Information
 - 13.2.2 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.2.3 Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.2.4 Boehringer Ingelheim Main Business Overview
 - 13.2.5 Boehringer Ingelheim Latest Developments
- 13.3 Merck Animal Health
 - 13.3.1 Merck Animal Health Company Information
 - 13.3.2 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.3.3 Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Merck Animal Health Main Business Overview
 - 13.3.5 Merck Animal Health Latest Developments
- 13.4 Ceva Sant? Animale
 - 13.4.1 Ceva Sant? Animale Company Information
 - 13.4.2 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.4.3 Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Ceva Sant? Animale Main Business Overview
 - 13.4.5 Ceva Sant? Animale Latest Developments
- 13.5 HIPRA
 - 13.5.1 HIPRA Company Information
 - 13.5.2 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.5.3 HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 HIPRA Main Business Overview
 - 13.5.5 HIPRA Latest Developments
- 13.6 Bioveta
 - 13.6.1 Bioveta Company Information
 - 13.6.2 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.6.3 Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.6.4 Bioveta Main Business Overview
- 13.6.5 Bioveta Latest Developments
- 13.7 Vaxxinova
 - 13.7.1 Vaxxinova Company Information
 - 13.7.2 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.7.3 Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.7.4 Vaxxinova Main Business Overview
 - 13.7.5 Vaxxinova Latest Developments
- 13.8 Nisseiken
 - 13.8.1 Nisseiken Company Information
 - 13.8.2 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.8.3 Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.8.4 Nisseiken Main Business Overview
 - 13.8.5 Nisseiken Latest Developments
- 13.9 Kyoto Biken Laboratories
 - 13.9.1 Kyoto Biken Laboratories Company Information
 - 13.9.2 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.9.3 Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.9.4 Kyoto Biken Laboratories Main Business Overview
 - 13.9.5 Kyoto Biken Laboratories Latest Developments
- 13.10 Pulike Biological Engineering
 - 13.10.1 Pulike Biological Engineering Company Information
 - 13.10.2 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.10.3 Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.10.4 Pulike Biological Engineering Main Business Overview
 - 13.10.5 Pulike Biological Engineering Latest Developments
- 13.11 Wuhan Keqian Biology
 - 13.11.1 Wuhan Keqian Biology Company Information
 - 13.11.2 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.11.3 Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine

Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Wuhan Keqian Biology Main Business Overview

13.11.5 Wuhan Keqian Biology Latest Developments

13.12 Huapai Biotechnology

13.12.1 Huapai Biotechnology Company Information

13.12.2 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine

Product Portfolios and Specifications

13.12.3 Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine

Sales, Revenue, Price and Gross Margin (2021-2026)

13.12.4 Huapai Biotechnology Main Business Overview

13.12.5 Huapai Biotechnology Latest Developments

13.13 TianKang Pharmaceutical

13.13.1 TianKang Pharmaceutical Company Information

13.13.2 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine

Product Portfolios and Specifications

13.13.3 TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine

Sales, Revenue, Price and Gross Margin (2021-2026)

13.13.4 TianKang Pharmaceutical Main Business Overview

13.13.5 TianKang Pharmaceutical Latest Developments

13.14 Qilu Animal Health

13.14.1 Qilu Animal Health Company Information

13.14.2 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product

Portfolios and Specifications

13.14.3 Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales,
Revenue, Price and Gross Margin (2021-2026)

13.14.4 Qilu Animal Health Main Business Overview

13.14.5 Qilu Animal Health Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Single Vaccine

Table 4. Major Players of Dual Vaccine

Table 5. Major Players of Others

Table 6. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 7. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Table 8. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2021-2026) & (\$ million)

Table 9. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)

Table 10. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026) & (US\$/Dose)

Table 11. Major Players of Oil-adjuvanted

Table 12. Major Players of Aqueous-adjuvanted

Table 13. Major Players of Others

Table 14. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Adjuvant Type (2021-2026) & (K Dose)

Table 15. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Adjuvant Type (2021-2026)

Table 16. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Adjuvant Type (2021-2026) & (\$ million)

Table 17. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Adjuvant Type (2021-2026)

Table 18. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Adjuvant Type (2021-2026) & (US\$/Dose)

Table 19. Major Players of Small Pack (Below 20 Doses per Vial)

Table 20. Major Players of Medium Pack (20-50 Doses per Vial)

Table 21. Major Players of Large Pack (Above 50 Doses per Vial)

Table 22. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)

Table 23. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)

Table 24. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Dose Pack Size (2021-2026) & (\$ million)

Table 25. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size (2021-2026)

Table 26. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026) & (US\$/Dose)

Table 27. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale by Application (2021-2026) & (K Dose)

Table 28. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)

Table 29. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2021-2026) & (\$ million)

Table 30. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2026)

Table 31. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026) & (US\$/Dose)

Table 32. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Company (2021-2026) & (K Dose)

Table 33. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)

Table 34. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026) & (\$ millions)

Table 35. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)

Table 36. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Price by Company (2021-2026) & (US\$/Dose)

Table 37. Key Manufacturers Inactivated Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution and Sales Area

Table 38. Players Inactivated Mycoplasma Hyopneumoniae Vaccine Products Offered

Table 39. Inactivated Mycoplasma Hyopneumoniae Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 40. New Products and Potential Entrants

Table 41. Market M&A Activity & Strategy

Table 42. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021-2026) & (K Dose)

Table 43. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share Geographic Region (2021-2026)

Table 44. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 45. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region (2021-2026)

Table 46. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country/Region (2021-2026) & (K Dose)

Table 47. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021-2026)

Table 48. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Country/Region (2021-2026) & (\$ millions)

Table 49. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country/Region (2021-2026)

Table 50. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)

Table 51. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)

Table 52. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 53. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 54. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)

Table 55. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026) & (K Dose)

Table 56. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2021-2026)

Table 57. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026) & (\$ millions)

Table 58. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 59. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)

Table 60. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)

Table 61. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 62. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 63. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by

Application (2021-2026) & (K Dose)

Table 64. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)

Table 65. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)

Table 66. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 67. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)

Table 68. Key Market Drivers & Growth Opportunities of Inactivated Mycoplasma Hyopneumoniae Vaccine

Table 69. Key Market Challenges & Risks of Inactivated Mycoplasma Hyopneumoniae Vaccine

Table 70. Key Industry Trends of Inactivated Mycoplasma Hyopneumoniae Vaccine

Table 71. Inactivated Mycoplasma Hyopneumoniae Vaccine Raw Material

Table 72. Key Suppliers of Raw Materials

Table 73. Inactivated Mycoplasma Hyopneumoniae Vaccine Distributors List

Table 74. Inactivated Mycoplasma Hyopneumoniae Vaccine Customer List

Table 75. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)

Table 76. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 77. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 78. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 79. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)

Table 80. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 81. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 82. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 83. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 84. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 85. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by

Type (2027-2032) & (K Dose)

Table 86. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 87. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Application (2027-2032) & (K Dose)

Table 88. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 89. Zoetis Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 90. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 91. Zoetis Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 92. Zoetis Main Business

Table 93. Zoetis Latest Developments

Table 94. Boehringer Ingelheim Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 95. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 96. Boehringer Ingelheim Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 97. Boehringer Ingelheim Main Business

Table 98. Boehringer Ingelheim Latest Developments

Table 99. Merck Animal Health Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 100. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 101. Merck Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 102. Merck Animal Health Main Business

Table 103. Merck Animal Health Latest Developments

Table 104. Ceva Sant? Animale Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 105. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 106. Ceva Sant? Animale Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 107. Ceva Sant? Animale Main Business

Table 108. Ceva Sant? Animale Latest Developments

Table 109. HIPRA Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 110. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 111. HIPRA Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 112. HIPRA Main Business

Table 113. HIPRA Latest Developments

Table 114. Bioveta Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 115. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 116. Bioveta Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 117. Bioveta Main Business

Table 118. Bioveta Latest Developments

Table 119. Vaxxinova Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 120. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 121. Vaxxinova Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 122. Vaxxinova Main Business

Table 123. Vaxxinova Latest Developments

Table 124. Nisseiken Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 125. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 126. Nisseiken Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 127. Nisseiken Main Business

Table 128. Nisseiken Latest Developments

Table 129. Kyoto Biken Laboratories Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 130. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 131. Kyoto Biken Laboratories Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 132. Kyoto Biken Laboratories Main Business

Table 133. Kyoto Biken Laboratories Latest Developments

Table 134. Pulike Biological Engineering Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 135. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 136. Pulike Biological Engineering Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 137. Pulike Biological Engineering Main Business

Table 138. Pulike Biological Engineering Latest Developments

Table 139. Wuhan Keqian Biology Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 140. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 141. Wuhan Keqian Biology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 142. Wuhan Keqian Biology Main Business

Table 143. Wuhan Keqian Biology Latest Developments

Table 144. Huapai Biotechnology Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 145. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 146. Huapai Biotechnology Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 147. Huapai Biotechnology Main Business

Table 148. Huapai Biotechnology Latest Developments

Table 149. TianKang Pharmaceutical Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 150. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 151. TianKang Pharmaceutical Inactivated Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 152. TianKang Pharmaceutical Main Business

Table 153. TianKang Pharmaceutical Latest Developments

Table 154. Qilu Animal Health Basic Information, Inactivated Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 155. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 156. Qilu Animal Health Inactivated Mycoplasma Hyopneumoniae Vaccine Sales

(K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 157. Qilu Animal Health Main Business

Table 158. Qilu Animal Health Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Inactivated Mycoplasma Hyopneumoniae Vaccine

Figure 2. Inactivated Mycoplasma Hyopneumoniae Vaccine Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Growth Rate 2021-2032 (K Dose)

Figure 7. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2025)

Figure 10. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Single Vaccine

Figure 12. Product Picture of Dual Vaccine

Figure 13. Product Picture of Others

Figure 14. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type in 2026

Figure 15. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)

Figure 16. Product Picture of Oil-adjuvanted

Figure 17. Product Picture of Aqueous-adjuvanted

Figure 18. Product Picture of Others

Figure 19. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Adjuvant Type in 2026

Figure 20. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Adjuvant Type (2021-2026)

Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)

Figure 22. Product Picture of Medium Pack (20-50 Doses per Vial)

Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)

Figure 24. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size in 2026

Figure 25. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market

Share by Dose Pack Size (2021-2026)

Figure 26. Inactivated Mycoplasma Hyopneumoniae Vaccine Consumed in Large-scale Pig Farming Groups

Figure 27. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Large-scale Pig Farming Groups (2021-2026) & (K Dose)

Figure 28. Inactivated Mycoplasma Hyopneumoniae Vaccine Consumed in Breeding Pig Farms

Figure 29. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Breeding Pig Farms (2021-2026) & (K Dose)

Figure 30. Inactivated Mycoplasma Hyopneumoniae Vaccine Consumed in Animal Health Service Providers

Figure 31. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Animal Health Service Providers (2021-2026) & (K Dose)

Figure 32. Inactivated Mycoplasma Hyopneumoniae Vaccine Consumed in Others

Figure 33. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market: Others (2021-2026) & (K Dose)

Figure 34. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2025)

Figure 35. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application in 2025

Figure 36. Inactivated Mycoplasma Hyopneumoniae Vaccine Sales by Company in 2025 (K Dose)

Figure 37. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company in 2025

Figure 38. Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue by Company in 2025 (\$ millions)

Figure 39. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company in 2025

Figure 40. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Geographic Region (2021-2026)

Figure 41. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region in 2025

Figure 42. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 43. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$ millions)

Figure 44. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 45. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue

2021-2026 (\$ millions)

Figure 46. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 47. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$ millions)

Figure 48. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 49. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$ millions)

Figure 50. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025

Figure 51. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)

Figure 52. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 53. Americas Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 54. United States Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 55. Canada Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 56. Mexico Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 57. Brazil Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 58. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region in 2025

Figure 59. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2021-2026)

Figure 60. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 61. APAC Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 62. China Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 63. Japan Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 64. South Korea Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 65. Southeast Asia Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 66. India Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 67. Australia Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 68. China Taiwan Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 69. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025

Figure 70. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)

Figure 71. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 72. Europe Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 73. Germany Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 74. France Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 75. UK Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 76. Italy Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 77. Russia Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 78. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)

Figure 79. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 80. Middle East & Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 81. Egypt Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 82. South Africa Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 83. Israel Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 84. Turkey Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth

2021-2026 (\$ millions)

Figure 85. GCC Countries Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 86. Manufacturing Cost Structure Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine in 2026

Figure 87. Manufacturing Process Analysis of Inactivated Mycoplasma Hyopneumoniae Vaccine

Figure 88. Industry Chain Structure of Inactivated Mycoplasma Hyopneumoniae Vaccine

Figure 89. Channels of Distribution

Figure 90. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Forecast by Region (2027-2032)

Figure 91. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Region (2027-2032)

Figure 92. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Type (2027-2032)

Figure 93. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Type (2027-2032)

Figure 94. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Application (2027-2032)

Figure 95. Global Inactivated Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Inactivated Mycoplasma Hyopneumoniae Vaccine Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GAA52C073858EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAA52C073858EN.html>